title: Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine.
abstract: Recurring waves of peri-infarct depolarizations (PIDs) propagate across gray matter in the hours and days following stroke, expanding the primary site of injury. Ischemic depolarization (termed anoxic depolarization or AD in live brain slices) is PID-like but immediately arises in the more metabolically compromised ischemic core. This causes dramatic neuronal and astrocyte swelling and dendritic beading with spine loss within minutes, resulting in acute cell death. AD is evoked in rodent neocortical slices by suppressing the Na(+)/K(+)-ATPase pump with either oxygen/glucose deprivation (OGD) or exposure to ouabain. The process driving AD and PIDs remains poorly understood. Here we show that dibucaine is a potent drug inhibiting AD because of its high binding affinity to the Na(+) channel. Field recording reveals that, when superfused with ouabain (5 min), neocortical slices pretreated with 1 μM dibucaine for 45 min display either no AD or delayed AD onset compared with untreated controls. If ouabain exposure is extended to 10 min, 1 μM dibucaine is still able to delay AD onset by ∼ 60%. Likewise, it delays OGD-evoked AD onset by ∼ 54% but does not depress action potentials (APs) or evoked orthodromic field potentials. Increasing dibucaine to 10 μM inhibits AP firing, gradually putting the slice into a stasis that inhibits AD onset but also renders the slice functionally quiescent. Two-photon microscopy reveals that 10 μM dibucaine pretreatment prevents or helps reverse ouabain-induced structural neuronal damage. Although the therapeutic range of dibucaine is quite narrow, dibucaine-like drugs could prove therapeutically useful in inhibiting PIDs and their resultant neuronal damage.
authors.affiliation: Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada.
authors.forename: Heather A
authors.initials: HA
authors.lastname: Douglas
authors.forename: Jennifer K
authors.initials: JK
authors.lastname: Callaway
authors.forename: Jeremy
authors.initials: J
authors.lastname: Sword
authors.forename: Sergei A
authors.initials: SA
authors.lastname: Kirov
authors.forename: R David
authors.initials: RD
authors.lastname: Andrew
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001253:Astrocytes / Q000473:pathology; D003712:Dendrites / Q000473:pathology; D003992:Dibucaine / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D020925:Hypoxia-Ischemia, Brain / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D009474:Neurons / Q000473:pathology; D010042:Ouabain / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D020521:Stroke / Q000150:complications*
chemical_list: D004791:Enzyme Inhibitors; D026941:Sodium Channel Blockers; D010042:Ouabain; D000254:Sodium-Potassium-Exchanging ATPase; D003992:Dibucaine